ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

Inclusion Criteria:

Male and female participants who are healthy Body mass index (BMI) of 17.5 to 30.5 kg/m2;
and a total body weight >50 kg

Exclusion Criteria:

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological,
dermatological, or allergic disease

- Any condition possibly affecting drug absorption

- Known immunodeficiency.

- Infection with hepatitis B or hepatitis C viruses

- acute or chronic infections or infection history judged to be clinically significant
by the investigator

- History of any lymphoproliferative disorder

- known present or a history of malignancy other than a successfully treated or excised
non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in
situ.

- live (attenuated) vaccines within 6 weeks prior to the first dose of investigational
product.